MARCH 1992

VOLUME 92 NUMBER 3

THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION

ORIGINAL CONTRIBUTION

BRIEF REPORTS

REVIEW ARTICLE

CLINICAL PRACTICE/LABORATORY MEDICINE

continued on page **245**

JAOA—THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION (USPS 469-110) is published monthly by the AMERICAN OSTEOPATHIC ASSOCIATION
142 East Ontario Street, Chicago, IL 60611-2864. Telephone 312/280-5800

VBPA

ISSN 0098-6151

This publication is available in microform. University Microfilms International, 300 North Zeeb Road, Ann Arbor, MI 48106 U.S.A.

Subscription Rates: US $40.00 per year; single copy, $4.00; Canada and foreign, $70.00 per year; single copy, $7.00; Second-class postage paid at Chicago, IL and at additional mailing offices.

Change of Address: Six to eight weeks prior to moving, please clip the mailing label from the most recent issue, and send it along with your new address (including ZIP code) to the department designated below. DOs and osteopathic students direct changes to the attention of the MEMBERSHIP DEPARTMENT. All other subscribers: direct changes to the attention of the CIRCULATION DEPARTMENT.

Postmaster: Send form 3579 to JAOA — The Journal of the American Osteopathic Association, 142 East Ontario Street, Chicago, IL 60611-2864.

Ceclor®
cefaclor

When there's greater concern for adults with respiratory infections*...



MAXIMIZE THE POSITIVE...

High susceptibilities of common bacterial respiratory pathogens

Pathogen	Susceptibility† to Ceclor	
Haemophilus influenzae[1‡] (includes β-lactamase-producing strains)	**98.9%**	(558/564 isolates)[§]
Streptococcus pneumoniae[1‡]	**99.8%**	(486/487 isolates)[§]
Moraxella catarrhalis[1‡] (includes β-lactamase-producing strains)	**100%**	(378/378 isolates)[§]
Staphylococcus aureus[2]	**100%**	(30/30 isolates)

The above in vitro data are available, but their clinical significance is unknown.

*Ceclor is indicated for the treatment of upper respiratory infections due to susceptible strains of *Streptococcus pyogenes* and for lower respiratory infections due to susceptible strains of *S. pneumoniae, H. influenzae,* and *S. pyogenes* (group A β-hemolytic streptococci).

† Includes susceptible and moderately susceptible strains.

‡ 1990 national surveillance study of major respiratory pathogens.

§ Isolates were obtained from respiratory fluids.

MINIMIZE THE NEGATIVE

Knowledge of the extent of GI absorption...allows prediction of the likelihood of GI side effects."[3]

95% "...cefaclor [is] almost completely absorbed [95%]...."[4]

1.4% In clinical studies with cefaclor, "diarrhea [was] reported by 1.4% of patients [113/8346]...."[5]

See adjacent page for brief summary of prescribing information.

1. *Antimicrob Agents Chemother.* 1990;34:2075-2080.
2. *Eur J Clin Microbiol Infect Dis.* 1990;9:685-691.
3. *Clin Ther.* 1991;13:189-193.
4. *DICP, Ann Pharmacother.* 1990;24:45-51.
5. *Clin Ther.* 1988;11(suppl A):63-72.

Lilly

Coming in. . .

THE DO

Neurologic disorders will be explored in the April issue of *The DO*. Articles will describe investigational drugs for Alzheimer's disease, explain recent discoveries related to multiple sclerosis, and offer advice on treating the complications of Parkinson's disease.

The April issue also will include coverage of an invitational conference sponsored by the National Board of Osteopathic Medical Examiners. And March's personality profile will be on Rear Adm Hugh P. Scott, DO, the highest ranking osteopathic physician in the Navy.

Future issues of JAOA

- "The office diagnosis of lower extremity venous insufficiency and treatment with the use of nonprescription support hose"
- "Laterally transposed pelvis: A new and proper name for an old problem"
- "HIV testing: Update"
- "A clinical study of the osteopathic management of children with neurological or medical problems at the Osteopathic Center for Children"
- "Training medical students in behavioral medicine"
- "The physiologic role and clinical significance of reverse cholesterol transport"
- "The varied clinical presentations of meningococcal infection"
- "Autologous blood transfusion: Standard of care for the 1990s"
- "Intern orientation: Obstacle or opportunity?"
- "Parietal bone mobility in the anesthetized cat"
- "Lyme disease: A review"
- "Suggestions for diagnosing avascular necrosis of the hip in the 1990s"

MARCH 1992

THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION

CLINICAL PRACTICE/HIV DIALOGUES AND MANAGEMENT

MEDICAL EDUCATION/PROGRAM DIRECTOR'S NOTEBOOK

SPECIAL COMMUNICATION

EDITORIAL

DEPARTMENTS

COVER

A metered dose inhaler is used in the treatment of asthma. Beginning on page **343**, Robert G. Garmon, DO, and Richard B. Zemenick, DO, review this and other modes of therapy used for the emergency treatment of acute severe asthma.

Announcing the first of a new NSAID class

FOR OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS



Announcing the first of a new NSAID class

NEW

RELAFEN®

nabumetone

- Efficacy comparable to aspirin
- Convenient once-a-day dosing

For the treatment of osteoarthritis and rheumatoid arthritis

- Efficacy comparable to aspirin in U.S. clinical trials[1]

Relafen **(1000 mg/day) is as effective as aspirin (3600 mg/day)**

In osteoarthritis[1]



Double-blind comparative trial of 332 patients.

In rheumatoid arthritis[2]



Double-blind comparative trial of 228 patients.

Please see accompanying brief summary of prescribing information.

Arthritis treatment with a low incidence of peptic ulcers

A low incidence of peptic ulcers in U.S. clinical studies of *Relafen* 1000 to 2000 mg/day

Time period	Cumulative incidence of peptic ulcers	95% confidence intervals	Number of patients* 1000 mg	1500 mg	2000 mg
3 to 6 months	0.3%	(0.0%, 0.6%)	1064	712	84
up to 1 year	0.5%	(0.1%, 0.9%)	833	614	69
up to 2 years	0.8%	(0.3%, 1.3%)	540	513	46

- Other G.I. symptoms comparable to other NSAIDs, including diarrhea (14%), dyspepsia (13%) and abdominal pain (12%)

*Patients may have been treated at more than one dosage level.

Lower incidence of endoscopic lesions† than ibuprofen‡[2]

Three-month endoscopic comparison of Relafen®, ibuprofen and ibuprofen plus Cytotec® in 167 patients



†The trials were not designed to correlate symptoms and endoscopy scores. The clinical relevance of these endoscopy findings, i.e., either G.I. symptoms or serious G.I. events, is not known.

‡ $P=0.013$.
§ Lesions defined as >5 mm.
‖ Cytotec® (misoprostol), G.D. Searle & Co.

NEW

RELAFEN®
NABUMETONE

For osteoarthritis and rheumatoid arthritis

Please see accompanying brief summary of prescribing information.

Over 5,000,000 prescriptions dispensed worldwide

- Evaluated in clinical studies with over 40,000 patients[2]
- Available in over 15 countries
- Eight years of worldwide clinical experience

Convenient once-a-day dosing

- Usual starting dose 1000 mg/day, taken as two 500 mg tablets*



- Dosage can be titrated up to 2000 mg/day*
- Can be taken with or without food
- Food increases the rate but not the extent of absorption

* Please see dosage and administration section of accompanying brief summary of prescribing information.

NEW

RELAFEN®
nabumetone

For osteoarthritis and rheumatoid arthritis

Announcing the first of a new NSAID class

NEW

RELAFEN®

NABUMETONE

For osteoarthritis and rheumatoid arthritis

- Efficacy comparable to aspirin
- Low incidence of peptic ulcers
- Other G.I. symptoms comparable to other NSAIDs, including diarrhea (14%), dyspepsia (13%) and abdominal pain (12%)
- Convenient once-a-day dosing
- Starting dose 1000 mg/day given as two 500 mg tablets
- Can be titrated up to 2000 mg/day



Please see accompanying brief summary of prescribing information.

SB
SmithKline Beecham
Pharmaceuticals
Philadelphia, PA 19101

RL202

Now! Zostrix® (Capsaicin 0.025% w/w

Topical Pain Therapy That Works Where It Hurts



Greater safety

Topical application alleviates concerns about organ toxicity or drug interactions with concomitant therapy.

Unique mode of action

Zostrix contains capsaicin which depletes substance P, a neurotransmitter known to exacerbate pain and inflammation in arthritic joints.[2] Through this mechanism, Zostrix provides pain control as monotherapy or enhances the efficacy of systemic regimens.

Zostrix Cream

(Capsaicin 0.025% w/w)

References

1. Enhanced pain control in patients with osteoarthritis and rheumatoid arthritis following treatment with topical capsaicin. Study Report #87-04. Data on file, GenDerm Corporation, Northbrook, IL 60062.
2. Harris ED. Rheumatoid arthritis: pathophysiology and implications for therapy. *New England Journal of Medicine.* 1990;322(18):1277-1289.

Cream for Arthritis Pain

Effective in Both Osteoarthritis and Rheumatoid Arthritis



Double-blind, randomized, placebo-controlled multicenter trial (n = 101)[1]



Zostrix® (Capsaicin 0.025% w/w) Cream
Topical Analgesic

Description: Zostrix Cream contains capsaicin, 0.025% w/w, in an emollient base containing benzyl alcohol, cetyl alcohol, glyceryl monostearate, isopropyl myristate, polyoxyethylene stearate blend, purified water, sorbitol solution and white petrolatum. Capsaicin is a naturally occurring substance derived from plants of the Solanaceae family with the chemical name trans-8-methyl-N-vanillyl-6-nonenamide. Capsaicin is a white crystalline powder with a molecular weight of 305.4. It is practically insoluble in water but very soluble in alcohol, ether and chloroform.

Action: Although the precise mechanism of action of capsaicin is not fully understood, current evidence suggests that capsaicin renders skin and joints insensitive to pain by depleting and preventing reaccumulation of substance P in peripheral sensory neurons. Substance P is thought to be the principal chemomediator of pain impulses from the periphery to the central nervous system. In addition, substance P has been shown to be released into joint tissues and activate inflammatory mediators involved with the pathogenesis of rheumatoid arthritis.

Indication: Zostrix is indicated for the temporary relief of peripheral neuralgias such as the pain following shingles (herpes zoster). Zostrix is also indicated for the temporary relief of the pain associated with rheumatoid arthritis and osteoarthritis.

Warnings: FOR EXTERNAL USE ONLY. Avoid contact with eyes and broken or irritated skin. Do not bandage tightly. If condition worsens, or does not improve after 28 days, discontinue use of this product and consult your physician. **Keep this and all drugs out of the reach of children.** In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

Directions: Adults and children 2 years of age and older: Apply Zostrix to affected area 3 to 4 times daily. Transient burning may occur upon application, but usually disappears in 72 hours. Application schedules of less than 3 to 4 times a day may not provide optimum pain relief and the burning sensation may persist. **Wash hands immediately after applying Zostrix.**

How Supplied:
1.5 oz tube (NDC 52761-552-45)
3.0 oz tube (NDC 52761-552-85)
Store at room temperature.
U.S. Patent Nos. 4486450 and 5536404

GenDerm Corporation
Lincolnshire, IL 60069

GENDERM®

knoll®
BASF Group